Drawing for CALLIDA

USPTO serial 76466639

CALLIDA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
KIM, YONG OH
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CALLIDA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

DONNA B. ROSE

RADOJE DRMANAC670 ALMANOR AVESUNNYVALE, CA 94085UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical and biological reagents and compounds, namely, nucleic acids, amino acids, polypeptides, enzymes, antibodies, lipids, carbohydrates and serum for research and development, forensic or scientific use; test and sample preparation kits for scientific or forensic use comprised of chemical and biological reagents, nucleic acids, enzymes, solid matrix materials, and consumables for laboratory use, namely pipette tips, glass bottles, glass cover slips, glass slides, plastic tubes, plastic containers, and tube racks; test kits for detecting nucleic acids, sequences of nucleic acids, and proteins interacting with nucleic acidsACTIVE—
005Diagnostic medical reagents and compounds, namely, nucleic acids, amino acids, polypeptides, enzymes, antibodies, lipids, carbohydrates and serum; Diagnostic test and sample preparation kits for medical use comprised of chemical and biological reagents, nucleic acids, enzymes, reagents for analysis of nucleic acids and proteins, solid matrix materials, and consumables for laboratory use, namely, pipette tips, glass bottles, glass cover slips, glass slides, plastic tubes, plastic containers, tube racks; medical diagnostic test kits for detecting pathogens and analytes in organisms, including human, and in the environmentACTIVE—
009Bioanalytical devices containing nucleic acid and other reagents for analysis of nucleic acids and proteins, namely, microarrays, microparticles, nano-particles, and microfluidic chips; laboratory equipment, namely DNA sequencers, DNA analyzers, DNA preparation and extraction instruments, and DNA hybridization instruments, for use in handling reagents, preparing nucleic acid samples and screening nucleic acid samples, and laboratory equipment, namely, nucleic acid synthesizers, nucleic acid cross-linking equipment, nucleic acid amplification apparatus, and microarray/biochip scanners and detectors, for use in detecting the presence of analytes in samples, identifying molecular information about the samples, and automating the assay processes; equipment for making molecular arrays, biochips and bioanalytical devices, namely, microarray spotters, microarray printers, and liquid and sample handling and pipetting instruments; computer software for the collection, analysis and management of nucleic acid data, protein data, chemical data and biological data for use in the field of scientific research and commercial developmentACTIVE—
042Nucleic acid sample preparation, sequencing, genotyping and expression services for others; research and development services for others; research and development services for others in the fields of chemical or biological reagents, analytical devices, apparatus and instrument for use in product research and development, forensic analysis, medical diagnostics, separation and purification processes, environmental testing processes and industrial quality control processes; chemical screening analysis; providing databases of knowledge in the field of genomics and genetics, namely, catalogs of gene sequences, sequence variations, genotypes, phenotypes and related chemical and biological data for commercial use; licensing of intellectual property, namely technologies for analysis of nucleic acids and proteins, and knowledge databases for commercial and medical useACTIVE—
044Diagnostic, forensic and genetic medical testing services for others; providing databases of knowledge in the fields of genomics and genetics, namely, catalogs of gene sequences, sequence variations, genotypes, phenotypes and related chemical and biological data for medical useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 5, 2006UNDNUNDELIVERABLE MAIL - NO ACTION TAKEN—
May 30, 2006MAILPAPER RECEIVED—
May 8, 2006MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 8, 2006ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 6, 2005NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 14, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 25, 2005NPUBNOTICE OF PUBLICATION—
Mar 2, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 18, 2005ALIEASSIGNED TO LIE—
Feb 12, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 9, 2005XAECEXAMINER'S AMENDMENT ENTERED—
Feb 9, 2005CNEAEXAMINERS AMENDMENT MAILED—
Feb 8, 2005CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 13, 2004TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 1, 2004TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 18, 2004CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 18, 2004TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 20, 2004CNCFCONTINUATION OF FINAL REFUSAL MAILED—
Oct 19, 2004CNCFACTION CONTINUING A FINAL - COMPLETED—
May 24, 2004CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 24, 2004TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 17, 2004UNPRUNRESPONSIVE/DUPLICATE PAPER RECEIVED—
May 17, 2004FAXXFAX RECEIVED—
Dec 3, 2003CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 4, 2003CFITCASE FILE IN TICRS—
Sep 12, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 12, 2003MAILPAPER RECEIVED—
Mar 11, 2003CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 27, 2003DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance